Your browser doesn't support javascript.
loading
Use of a p64 MW Flow Diverter with Hydrophilic Polymer Coating (HPC) and Prasugrel Single Antiplatelet Therapy for the Treatment of Unruptured Anterior Circulation Aneurysms: Safety Data and Short-term Occlusion Rates.
Hellstern, V; Aguilar Pérez, M; Henkes, E; Donauer, E; Wendl, C; Bäzner, H; Ganslandt, O; Henkes, H.
Afiliación
  • Hellstern V; Neuroradiologische Klinik, Kopf- und Neurozentrum, Klinikum Stuttgart, Stuttgart, Germany. v.hellstern@klinikum-stuttgart.de.
  • Aguilar Pérez M; Neuroradiologische Klinik, Kopf- und Neurozentrum, Klinikum Stuttgart, Stuttgart, Germany.
  • Henkes E; Neuroradiologische Klinik, Kopf- und Neurozentrum, Klinikum Stuttgart, Stuttgart, Germany.
  • Donauer E; Klinik Für Neurochirurgie, Mediclin Krankenhaus Plau Am See, Plau Am See, Germany.
  • Wendl C; Institut Für Röntgendiagnostik, Zentrum Für Neuroradiologie, Universitätsklinikum Regensburg, Regensburg, Germany.
  • Bäzner H; Neurologische Klinik, Neurozentrum, Klinikum Stuttgart, Stuttgart, Germany.
  • Ganslandt O; Neurozentrum, Neurochirurgische Klinik, Klinikum Stuttgart, Stuttgart, Germany.
  • Henkes H; Neuroradiologische Klinik, Kopf- und Neurozentrum, Klinikum Stuttgart, Stuttgart, Germany.
Cardiovasc Intervent Radiol ; 45(9): 1364-1374, 2022 Sep.
Article en En | MEDLINE | ID: mdl-35562486
PURPOSE: To assess the safety and short-term occlusion rates in procedures using the p64 MW hydrophilic polymer-coated (HPC) flow diverter (FD) with prasugrel single antiplatelet therapy (SAPT) for the treatment of anterior circulation saccular aneurysms. METHODS: We retrospectively identified patients who underwent treatment of one or more intracranial anterior circulation saccular aneurysms between March 2020 and December 2021 with a p64 MW HPC FD and prasugrel SAPT with verified P2Y12 platelet receptor inhibition. Patients diagnosed with fusiform, dissecting, or recently ruptured aneurysms were excluded. Periprocedural and postprocedural complications, clinical outcomes, and angiographic follow-up results were evaluated. RESULTS: One hundred and two patients with 132 intracranial aneurysms met the inclusion criteria. Previous or concomitant treatments (e.g., coil occlusion) had been performed on 18 of these aneurysms. The technical success rate (i.e., implantation of the intended FD) was 100% with an average of 1.1 devices implanted per patient. Periprocedural and postprocedural complications occurred in 13.6% and 6.8% of these patients, respectively. No mortality or permanent clinical deterioration (i.e., modified Rankin scale score ≥ 3) were reported. Early follow-up digital subtraction angiography revealed aneurysmal occlusion rates of 72.6% and 83.8% at four and nine months, respectively. CONCLUSIONS: The implantation of a p64 MW HPC FD with prasugrel SAPT is safe and results in rapid, reliable and effective aneurysmal occlusion.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aneurisma Intracraneal / Embolización Terapéutica / Procedimientos Endovasculares Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Cardiovasc Intervent Radiol Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aneurisma Intracraneal / Embolización Terapéutica / Procedimientos Endovasculares Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Cardiovasc Intervent Radiol Año: 2022 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos